NCT04117087 — Sidney Kimmel Comprehensive Cancer Center… cancer vaccine trial
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
Registry record
| Registry ID | NCT04117087 ↗ |
|---|---|
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Collaborators | Bristol-Myers Squibb, National Cancer Institute (NCI), National Institutes of Health (NIH) |
| Phase | Phase 1 |
| Status | Active Not Recruiting |
| Indication | Colorectal Cancer, Pancreatic Cancer |
| Enrollment | 27 participants (target) |
| Start date | 2020-05-28 |
| Primary completion | 2027-06-01 (est.) |
| Last registry update | 27 Jul 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT04117087), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT04117087?
NCT04117087 (Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer) is registered on ClinicalTrials.gov as Phase 1, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Is NCT04117087 recruiting?
As of the 2026-07-27 registry update, NCT04117087 is listed as "Active Not Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT04117087?
The lead sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Collaborators: Bristol-Myers Squibb, National Cancer Institute (NCI), National Institutes of Health (NIH).
What condition does NCT04117087 study?
The registered conditions are Colorectal Cancer, Pancreatic Cancer. Primary completion is listed as 2027-06-01 (estimated).
Are results available for NCT04117087?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT04117087.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.